Almirall Advances Etherna's Intratumoral mRNA Therapy LAD116 to Clinical Development for Non-Melanoma Skin Cancer
核心洞察
Almirall has nominated LAD116 (搜索), an intratumoral mRNA/LNP therapy developed in collaboration with etherna (搜索), for IND-enabling studies targeting non-melanoma skin cancer (搜索).
The therapy is designed to generate a potent immune response directly within the tumor microenvironment (搜索) using etherna (搜索)'s proprietary mRNA and lipid nanoparticle platform technology.
The collaboration will now focus on manufacturing GMP-grade material for IND-enabling studies and intended Phase I clinical trials.
Almirall, a leading medical dermatology company, has nominated LAD116 (搜索) as a novel therapy targeting non-melanoma skin cancer (搜索) for further development in IND-enabling studies. The therapy is based on etherna (搜索)'s intratumoral mRNA/LNP platform, designed to generate a potent immune response directly within the tumor microenvironment (搜索).
Collaboration Milestone
The partnership between Almirall and etherna (搜索) has reached a critical development milestone with the preclinical candidate nomination of LAD116 (搜索). The collaboration will now shift focus to manufacturing and producing GMP-grade material for IND-enabling studies and intended Phase I clinical trials.
Bernard Sagaert, CEO of etherna (搜索), emphasized the success of the partnership: "This collaboration is a perfect example of what can be achieved when teams are fully aligned and driven to succeed. The combined efforts of both companies to discover and advance an mRNA-LNP based therapy to preclinical candidate nomination, on time and on budget, has been outstanding."
Innovative Therapeutic Approach
LAD116 (搜索) represents an innovative intratumoral approach utilizing mRNA and lipid nanoparticle technology. The therapy is specifically designed to target non-melanoma skin cancer (搜索) by delivering therapeutic mRNA directly to the tumor site, potentially offering a more targeted treatment option for patients.
Karl Ziegelbauer, Chief Scientific Officer at Almirall, highlighted the company's commitment to innovation: "Almirall is committed to advancing innovation in medical dermatology to address significant unmet medical needs. We are very excited to advance this innovative intratumoral approach to potentially treat patients with non-melanoma skin cancer (搜索) and we are delighted to see rapid progress of our collaboration with etherna (搜索) based on their mRNA and LNP capabilities."
Technology Platform
Etherna (搜索) brings over a decade of expertise in mRNA and lipid nanoparticle technologies to the collaboration. The Belgium-based company, founded in 2013 as a spin-off from the Vrije Universiteit Brussel (VUB), has evolved from a developer of immunotherapies into a strategic partner for the global life sciences industry. The company provides pharma and biotech partners with an integrated suite of proprietary platforms, including customizable lipid nanoparticles (cLNPs) and advanced mRNA chemistry.
The company's capabilities span from early research and development to GMP manufacturing, with headquarters in Niel, Belgium, R&D facilities in Ghent, and commercial operations in the U.S. and Asia.